Printer Friendly

ADVANCED BIOLOGICAL SYSTEMS REPORTS ADDITIONAL, FAVORABLE TOXICITY TESTS FOR PLANT-BASED AIDS DRUGS, C-1983 AND R-1103

 ADVANCED BIOLOGICAL SYSTEMS REPORTS ADDITIONAL, FAVORABLE
 TOXICITY TESTS FOR PLANT-BASED AIDS DRUGS, C-1983 AND R-1103
 SALT LAKE CITY, Feb. 27 /PRNewswire/ -- Additional favorable findings, in a series of toxicity tests of plant-based pharmaceuticals developed by Swiss doctor Jozsef Roka for treating AIDS, were released today by Advanced Biological Systems, Inc. (OTC: AVBS).
 In further preliminary tests, no evidence of reproductive toxicity was found in fetuses of rats which received ten times the calculated human doses of C-1983 (Carciviren-V) through intra-muscular injection. All fetuses were within the normal weight range with color and motility normal. No microscopic abnormalities were found in fetuses.
 The studies, conducted by Professor The Honorable Manley E. West of the University Hospital of the West Indies in Kingston, Jamaica, follow earlier acute and sub-chronic toxicity and gross and micro-pathological tests of C-1983 by West which revealed no adverse effects in rats or in cell tissues of rat organs.
 Preliminary tests of another Roka pharmaceutical for the treatment of AIDS, R-1103 (Rovital-V), have likewise revealed no evidence of harmful side effects. The drug, which is administered through oral drops, showed no undue toxicity following the completion of acute and sub-chronic toxicity and gross pathological studies by West. Microscopic pathology results, near completion, have also revealed no abnormalities.
 Several hundred patients have already been treated with the Roka pharmaceuticals in Switzerland and Tanzania, providing reports of significant remission of AIDS symptoms, return of appetite and body weight, and the ability to resume active lifestyles without adverse side effects. The company has also released a report which cites anti- oxidants and other properties of plant-based therapies as potential explanations for the Roka pharmaceuticals' efficacy.
 Scientific research with pharmaceuticals requires identification of potential side effects and proof of effectiveness. Findings of no undue toxicity are important because they remove concerns of harmful side effects and facilitate the commencement and speed of effectiveness studies.
 Both C-1983 and R-1103 are utilized in the Roka AIDS treatment program which will be the subject of controlled, double blind clinical studies at the University Hospital of the West Indies, scheduled to begin shortly. Funding for the studies is in place and for final protocol adjustments by the research team are nearly completed, according to university and company officials.
 Advanced Biological Systems, Inc., a publicly-owned Delaware corporation, is engaged in the delivery of care for immune deficiency conditions through treatments which include plant-sourced products. The company recently reported it has completed its year-end audit and formally applied for a NASDAQ listing.
 -0- 2/27/92
 /CONTACT: Emanuel A. Floor or Paul Mortensen, 801-521-8000; or Robert Ferris, 212-921-1060, all for Advanced Biological Systems/
 (AVBS) CO: Advanced Biological Systems, Inc. ST: Utah IN: MTC SU:


GK -- NY056 -- 3302 02/27/92 13:21 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 27, 1992
Words:455
Previous Article:GLOBAL INCOME PLUS FUND SETS RECORD DATE FOR 1992 ANNUAL MEETING OF SHAREHOLDERS
Next Article:BLESSINGS SETS RECORD DATE FOR SHAREHOLDERS
Topics:


Related Articles
JAMAICAN RESEARCHERS GIVE GREEN LIGHT TO HUMAN CLINICAL TRIALS FOR PROMISING PLANT-BASED AIDS DRUG DEVELOPED IN SWITZERLAND
ADVANCED BIOLOGICAL SYSTEMS COMPLETES $2 MILLION PRIVATE PLACEMENT; INTENDS TO FILE FOR NASDAQ LISTING, PROCEED WITH CLINIC & RESEARCH PLANS
UNIVERSITY OF LONDON INDEPENDENT LAB STUDIES VERIFY POWERFUL ANTI- OXIDANT PROPERTIES OF ADVANCED BIOLOGICAL SYSTEMS' AIDS COMPOUNDS
ADVANCED BIOLOGICAL SYSTEMS' LICENSEE BEGINS TREATING AIDS PATIENTS IN THE CARIBBEAN; ROKA TREATMENT USES PLANT-BASED THERAPEUTICS
THE LIPOSOME COMPANY REACQUIRES ALL RIGHTS TO FLAGSHIP ANTI-FUNGAL DRUG TLC ABLC SHOWING ENCOURAGING RESULTS IN OVER 350 PATIENTS
CORTECH BEGINS PRECLINICAL DEVELOPMENT OF COMPOUNDS FOR SULFA ALLERGY TREATMENT IN AIDS PATIENTS
BOSTON BIOMEDICA, INC. AWARDED WORLD-WIDE LICENSE TO ANTI-AIDS COMPOUNDS
VERY LOW DOSAGE OF CANCER DRUG SIGNIFICANTLY BOOSTS KILLER T CELLS
TRIANGLE PHARMACEUTICALS ACQUIRES EXCLUSIVE RIGHTS TO THREE ANTIVIRAL COMPOUNDS
The Liposome Company's ABELCET Approved in Greece For Treatment of Severe Systemic Fungal Infections

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters